Creo Medical GroupCMEOF 53 PB Ratio is 1.23 as of Jun. 28, 2026, which is 12% below its 10-year median of 1.40. GuruFocus rates CMEOF with a GF Score™ of 53/100 and a GF Value™ of $0.25. The stock has 6 warning signs investors should review. Among 787 Medical Devices & Instruments companies, Creo Medical Group ranks better than 75.73% on this metric.
The historical rank and industry rank for Creo Medical Group's PB Ratio or its related term are showing as below:
CMEOF'
s PB Ratio Range Over the Past 10 Years
Min: 0.62 Med: 1.4 Max: 5.62
Current: 1.12
During the past 11 years, Creo Medical Group's highest PB Ratio was 5.62. The lowest was 0.62. And the median was 1.40.
CMEOF's PB Ratio is ranked better than 75.73% of 787
companies
in the Medical Devices & Instruments industry
Industry Median: 1.99
vs CMEOF: 1.12
During the past 12 months, Creo Medical Group's average Book Value Per Share Growth Rate was 17.50% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -22.70% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -25.40% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 25.30% per year.
During the past 11 years, the highest 3-Year average Book Value Per Share Growth Rate of Creo Medical Group was 289.10% per year. The lowest was -35.90% per year. And the median was 4.90% per year.
Back to Basics: PB Ratio
Creo Medical Group (OTCPK:CMEOF) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Creo Medical Group PB Ratio Related Terms
Creo Medical Group PB Ratio Historical Data
* Premium members only.
The historical data trend for Creo Medical Group's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Creo Medical Group's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Creo Medical Group PB Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Creo Medical Group's PB Ratio distribution charts can be found below:
* The bar in red indicates where Creo Medical Group's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Creo Medical Group (CMEOF) has a PB Ratio of 1.23 as of Jun. 28, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Creo Medical Group and its competitors. This is 12% below median its historical median of 1.40. Over the past decade, Creo Medical Group's PB Ratio has ranged from 0.62 to 5.62. According to the industry distribution chart, Creo Medical Group ranks #191 out of 787 companies in the Medical Devices & Instruments industry, placing it in the top 24.3%.
Is Creo Medical Group's PB Ratio too high?
Creo Medical Group's current PB Ratio of 1.23 is 12% below median its 10-year median of 1.40. Over the past 10 years, this metric has ranged from a low of 0.62 to a high of 5.62. The Medical Devices & Instruments industry median PB Ratio is 1.99. Creo Medical Group's value of 1.23 is 38.2% below this industry median. Based on the distribution chart, Creo Medical Group ranks #191 out of 787 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Creo Medical Group has a GF Score™ of 53/100, reflecting its overall financial health beyond just this single metric.
How does Creo Medical Group's PB Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Creo Medical Group ranks #191 out of 787 companies for PB Ratio. This places Creo Medical Group in the top 24% of its industry — outperforming the majority of peers. The industry median PB Ratio is 1.99. Creo Medical Group's value of 1.23 is 38.2% below this benchmark. Historically, Creo Medical Group's own PB Ratio has ranged from 0.62 to 5.62 over the past decade. While the company's 10-year median is 1.40 vs. the industry median of 1.99, Creo Medical Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Devices & Instruments company?
The median PB Ratio among Medical Devices & Instruments companies is 1.99, based on 787 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Creo Medical Group's current PB Ratio of 1.23 is 38.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Creo Medical Group and its competitors. For the Medical Devices & Instruments industry, the median PB Ratio is 1.99 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Creo Medical Group's current PB Ratio is 1.23, which is 12% below median its own 10-year median of 1.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Creo Medical Group stock overvalued right now?
Creo Medical Group (CMEOF) has a current PB Ratio of 1.23. The stock's GF Value™ is $0.25, compared to a current price of $0.20 — trading 20% below its estimated fair value. The current PB Ratio is 1.23, which is 12% below median its 10-year median of 1.40 and 38.2% below the Medical Devices & Instruments industry median of 1.99. Creo Medical Group's overall GF Score™ is 53/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Creo Medical Group (CMEOF), the current PB Ratio is 1.23 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Creo Medical Group (CMEOF) Overvalued in 2026?
Based on GuruFocus' analysis, Creo Medical Group stock appears to be undervalued.
The current stock price of $0.20 is trading 20% below its estimated GF Value™ of $0.25.
Key valuation signals for CMEOF:
PB Ratio: 1.23 (12% below median its 10-year median of 1.40)
GF Value™: $0.25 vs. price of $0.20 (20% below fair value)
Industry Position: 38.2% below the Medical Devices & Instruments median (#191 of 787)
No single metric tells the full story. See the CMEOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Creo Medical Group PLC is a medical device company engaged in providing services in the field of surgical endoscopy. The company has developed a platform called Croma which is an electrosurgical platform to deliver microwave and bipolar radiofrequency through a single accessory port. The reportable segment of the company is the research and development of electrosurgical medical devices relating to the field of surgical endoscopy. Geographically, the company generates a majority of its revenue from United Kingdom and the rest from Europe and the rest of the world.
53GF Score
Get the complete analysis for CMEOF
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CMEOF has been successfully added to your 
